Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arnon P Kater

Showing results (1-10 of 209) with videos related to

Pageof 21
Sort By:
Blood|August 21, 2025
A burden too high for CAR T cells in CLLArnon P Kater, Maria Themeli
The New England Journal of Medicine|July 5, 2023
Inhibiting BTK in Chronic Lymphocytic LeukemiaArnon P Kater, Barbara Eichhorst
Blood|July 5, 2014
miR in CLL: more than mere markers of prognosis?Arnon P Kater, Eric Eldering
Hematology. American Society of Hematology. Education Program|December 7, 2024
Relapsed/refractory CLL: the role of allo-SCT, CAR-T, and T-cell engagersArnon P Kater, Tanya Siddiqi
The Lancet. Oncology|December 8, 2018
Ibrutinib: searching for a partner drugArnon P Kater, Jennifer R Brown
Blood|May 8, 2020
CAR-T and ibrutinib vs CLL: sequential or simultaneous?Arnon P Kater, J Joseph Melenhorst
Hemasphere|March 21, 2022
Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?Iris de Weerdt, Arnon P Kater
Blood|March 24, 2022
Do CARs finally hit the CLL road?Arnon P Kater, J Joseph Melenhorst
The Lancet. Oncology|February 1, 2024
The GLOW trial in chronic lymphocytic leukaemia - Authors' replyCarsten U Niemann, Arnon P Kater
Clinical Lymphoma, Myeloma & Leukemia|June 10, 2010
Standards for the treatment of relapsed chronic lymphocytic leukemia: a case-based studyArnon P Kater, Sanne H Tonino
Pageof 21

Showing results (1-10 of 209) with videos related to

Sort By:
Pageof 21
Blood|August 21, 2025
A burden too high for CAR T cells in CLLArnon P Kater, Maria Themeli
The New England Journal of Medicine|July 5, 2023
Inhibiting BTK in Chronic Lymphocytic LeukemiaArnon P Kater, Barbara Eichhorst
Blood|July 5, 2014
miR in CLL: more than mere markers of prognosis?Arnon P Kater, Eric Eldering
Hematology. American Society of Hematology. Education Program|December 7, 2024
Relapsed/refractory CLL: the role of allo-SCT, CAR-T, and T-cell engagersArnon P Kater, Tanya Siddiqi
The Lancet. Oncology|December 8, 2018
Ibrutinib: searching for a partner drugArnon P Kater, Jennifer R Brown
Blood|May 8, 2020
CAR-T and ibrutinib vs CLL: sequential or simultaneous?Arnon P Kater, J Joseph Melenhorst
Hemasphere|March 21, 2022
Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?Iris de Weerdt, Arnon P Kater
Blood|March 24, 2022
Do CARs finally hit the CLL road?Arnon P Kater, J Joseph Melenhorst
The Lancet. Oncology|February 1, 2024
The GLOW trial in chronic lymphocytic leukaemia - Authors' replyCarsten U Niemann, Arnon P Kater
Clinical Lymphoma, Myeloma & Leukemia|June 10, 2010
Standards for the treatment of relapsed chronic lymphocytic leukemia: a case-based studyArnon P Kater, Sanne H Tonino
Pageof 21